Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + H101 + Short-course Radiotherapy + XELOX for Locally Advanced Rectal Cancer
NCT07543848Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Immune Checkpoint Inhibitors, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, Oncorine in rectal adenocarcinoma, sponsored by Chongqing University Cancer Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
serplulimabOncorine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07543848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543848.